jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

Mar. 03, 2010

Dec. 17, 2018

jRCT2080221036

CS-1036 phase 2 study - dose response study of CS-1036 in patients with type 2 diabetes -

version:
date:

DAIICHI SANKYO Co.,Ltd.

http://www.daiichisankyo.co.jp/contact/clinical/index.html

Interventional

Multi-center, randomized, double-blind, placebo-controlled, dose response study.

2

1. Patients diagnosed with type 2 diabetes mellitus
2. Outpatient

1. Patient with type 1 diabetes mellitus
2. Patient with clinically significant diabetic complications

70age old over
20age old under

Both

Patients with Type 2 Diabetes

investigational material(s)
Generic name etc : CS-1036
INN of investigational material :
Therapeutic category code : 396 Antidiabetic agents
Dosage and Administration for Investigational material : Oral

Postprandial glucose

1. Fasting plasma glucose, insulin, glycoalbumin, and 1,5-anhydroglucitol
2. Safety and tolerability

DAIICHISANKYO Co.,Ltd.

JapicCTI-101069

History of Changes

No Publication date
5 Dec. 17, 2018 (this page) Changes
4 Jan. 27, 2011 Detail Changes
3 Jan. 27, 2011 Detail Changes
2 Mar. 03, 2010 Detail Changes
1 Mar. 03, 2010 Detail